ライフサイエンスコーパス: NMSC

1 NMSC and melanoma skin cancers were ascertained by annua

2 NMSC cases arising from patients served by a staff model

3 NMSC patients diagnosed between January 1, 1988, and Dec

4 NMSC patients were defined by a history of basal cell or

5 melanoma, corresponding to more than 450 000 NMSC cases and more than 10 000 melanoma cases each year

6 : 2.54; 95% CI: 0.95, 6.81; P-trend = 0.03), NMSC (HR(T3vs.T1): 3.49; 95% CI: 1.11, 11.0; P-trend = 0

7 : 1.79; 95% CI: 1.07, 2.99; P-trend = 0.03], NMSC (HR(T3vs.T1): 1.85; 95% CI: 1.06, 3.23; P-trend = 0

8 ons 18 years or older who had had at least 1 NMSC during the 1996-2008 period.

9 health care plan, diagnosed with at least 1 NMSC from 1996-2008 to determine risk of subsequent NMSC

10 the original cohort to those with at least 1 NMSC.

11 screen for isolates of ET-24 by testing 199 NMSC isolates of 51 different ETs.

12 eased numbers of NMSCs in the treated arm (2 NMSCs) versus the untreated arm (24 NMSCs).CONCLUSIONThe

13 d arm (2 NMSCs) versus the untreated arm (24 NMSCs).CONCLUSIONThe elimination of senescent fibroblast

14 A 6-year retrospective review of 2998 NMSC cases between February 26, 2007, and February 17, 2

15 )S(6)](4-):Mn(2+) at a molar ratio of 1:0.5; NMSC-1) with a unique arrangement within a disordered ne

16 es of data from 1988-2007 ascertained 11,742 NMSC patients.

17 Of all 2998 cases, we identified 805 NMSC-ASE cases: 137 IS and 668 IC.

18 ect of these drugs on the risk of additional NMSCs.

19 Numbers of AKs/NMSCs were recorded on both extremities for up to 36 mon

20 tions were identified by using 3 algorithms: NMSC International Classification of Diseases, Ninth Rev

21 supergene family is associated with altered NMSC risk in nontransplant patients, we examined allelis

22 that significantly increased the odds of an NMSC diagnosis were light skin color (OR, 5.79 [95% CI,

23 rFE)/other Na-Mn-Sn-S chalcogels (NMSC-2 and NMSC-3 with [Sn(2)S(6)](4-):Mn(2+) molar ratios of 1:1 a

24 ppression increases the risk of melanoma and NMSC among patients with IBD.

25 vors have an increased risk for melanoma and NMSC that occurred earlier than that observed among nonh

26 The risk of melanoma and NMSC was evaluated by incidence rate ratio (IRR) and by

27 partly reflecting an ageing population, and NMSC is more commonly seen in men.

28 They also suggest sunburn and NMSC etiologies are immunologically linked.

29 between photosensitizing medication use and NMSC.

30 965 cases was selected for chart review, and NMSCs were validated in 47.0% of ICD-9-CM-identified pat

31 lidation of administrative data to ascertain NMSC demonstrates respectable sensitivity and specificit

32 administrative data can be used to ascertain NMSC with high positive predictive values with either IC

33 be used as sampling frames for ascertaining NMSC.

34 Because NMSCs are rarely lethal and most cancer registries do no

35 Associations were measured between NMSC and 221 SNPs in 26 NER genes.

36 In both NMSC and bladder tumors we found a high prevalence of EM

37 This association was primarily driven by NMSC, lymphoma, and lung cancer.

38 Neisseria meningitidis serogroup C (NMSC) isolates of electrophoretic type 24 (ET-24), as id

39 uency of Neisseria meningitidis serogroup C (NMSC) outbreaks in the United States has increased.

40 mtDNA) deletions in nonmelanoma skin cancer (NMSC) and in cutaneous photoaging was explored using a g

41 levels with risk of nonmelanoma skin cancer (NMSC) and melanoma, we evaluated the effects of vitamin

42 , and Australia for nonmelanoma skin cancer (NMSC) and melanoma.

43 B radiation against nonmelanoma skin cancer (NMSC) are exerted via signaling mechanisms involving the

44 DSCMs for residual nonmelanoma skin cancer (NMSC) before and after a brief training session (about 5

45 the development of nonmelanoma skin cancer (NMSC) by destabilizing the host genome.

46 increased risk of non-melanoma skin cancer (NMSC) compared to in the general population.

47 developed an SN1 of nonmelanoma skin cancer (NMSC) had a cumulative incidence of subsequent malignant

48 Nonmelanoma skin cancer (NMSC) has become the most common type of cancer in many

49 the US incidence of nonmelanoma skin cancer (NMSC) has been difficult.

50 isk of melanoma and nonmelanoma skin cancer (NMSC) in patients with IBD and how medications affect th

51 mortality rates for nonmelanoma skin cancer (NMSC) in the United States.

52 nd the incidence of nonmelanoma skin cancer (NMSC) is poorly understood.

53 is limited because non-melanoma skin cancer (NMSC) is predominantly formed on body sites which are 'u

54 he incidence of nonmelanomatous skin cancer (NMSC) is substantially higher among renal transplant rec

55 Non-melanoma skin cancer (NMSC) is the most common cancer in Caucasians worldwide.

56 Nonmelanoma skin cancer (NMSC) is the most common cancer worldwide and the most f

57 Non-melanoma skin cancer (NMSC) is the most common malignancy, whose public health

58 Nonmelanoma skin cancer (NMSC) occurs in photoexposed areas and is frequent in th

59 a periocular region nonmelanoma skin cancer (NMSC) or a nonperiocular NMSC causing a complication req

60 pected incidence of nonmelanoma skin cancer (NMSC) or other cancers, whereas those receiving combinat

61 Non-melanoma skin cancer (NMSC) represents a significant cause of morbidity and mo

62 linical marker for non-melanoma skin cancer (NMSC) risk.

63 Nonmelanoma skin cancer (NMSC) such as cutaneous squamous cell carcinoma (cSCC) i

64 in a series of 61 non-melanoma skin cancer (NMSC) tumors.

65 nt cancer excluding nonmelanoma skin cancer (NMSC) were 1.06 (95% CI, 1.02-1.09), 1.06 (95% CI, 1.02-

66 venting UVB-induced nonmelanoma skin cancer (NMSC) without displaying any overt toxicities.

67 a (typically called nonmelanoma skin cancer (NMSC)).

68 high incidence of non-melanoma skin cancer (NMSC), a preventative intervention would be desirable.

69 n cancer (overall), nonmelanoma skin cancer (NMSC), and basal cell carcinoma (BCC).

70 the development of non-melanoma skin cancer (NMSC), controlling for known confounders.

71 infected persons of nonmelanoma skin cancer (NMSC), defined as basal cell carcinoma (BCC) and squamou

72 the development of non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous

73 t options exist for nonmelanoma skin cancer (NMSC), including topical agents, surgery, or definitive

74 ographic surgery of nonmelanoma skin cancer (NMSC), inflammation in histologic frozen sections has be

75 s a risk factor for nonmelanoma skin cancer (NMSC), particularly squamous cell tumors.

76 and categorized as nonmelanoma skin cancer (NMSC), viral-linked and "other" cancers.

77 counted, except for nonmelanoma skin cancer (NMSC), where only the first was counted.

78 et B (UVB)-induced non-melanoma skin cancer (NMSC), which consists primarily of squamous cell carcino

79 nd a high risk for non-melanoma skin cancer (NMSC).

80 susceptibility to non-melanoma skin cancer (NMSC).

81 es for ascertaining nonmelanoma skin cancer (NMSC).

82 decreased risk of non-melanoma skin cancer (NMSC).

83 and progression of nonmelanoma skin cancer (NMSC).

84 for developing nonmelanomatous skin cancer (NMSC).

85 s cancers following nonmelanoma skin cancer (NMSC).

86 n increased risk of nonmelanoma skin cancer (NMSC).

87 c surgery (MMS) for nonmelanoma skin cancer (NMSC).

88 uding and excluding nonmelanoma skin cancer (NMSC); all malignancies were externally adjudicated.

89 f 191 patients with nonmelanoma skin cancer (NMSC; 81 SCC and 110 basal cell carcinoma (BCC)) and 176

90 .04, 0.02, and 0.02 for overall skin cancer, NMSC, and BCC, respectively.

91 n and increased risk of overall skin cancer, NMSC, and BCC.

92 Nonmelanoma skin cancers (NMSC) are among the most common malignancies in the worl

93 be carcinogenic in nonmelanoma skin cancers (NMSC), but the basis for potential viral contributions t

94 es usually exclude nonmelanoma skin cancers (NMSC), despite the large population affected.

95 ity and number of non-melanoma skin cancers (NMSCs) among 10 183 European Americans in the discovery

96 Non-melanoma skin cancers (NMSCs) are among the most common human malignancies.

97 Nonmelanoma skin cancers (NMSCs) are primarily diagnosed through paraffin section

98 Nonmelanoma skin cancers (NMSCs) are the most common cancers in fair-skinned popul

99 Non-melanoma skin cancers (NMSCs) are the most common malignancy among US Caucasian

100 Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloprolife

101 s cell carcinomas (nonmelanoma skin cancers (NMSCs)), data are insufficient to permit evidence-based

102 initiation of some nonmelanoma skin cancers (NMSCs), particularly in patients with the genetic disord

103 for primary facial nonmelanoma skin cancers (NMSCs), recurrence rates with Mohs micrographic surgery

104 risk of developing nonmelanoma skin cancers (NMSCs).

105 bo, respectively), nonmelanoma skin cancers (NMSCs; four vs. zero squamous cell carcinomas (SCCs)), a

106 ancies (excluding non-melanoma skin cancers [NMSCs]), post-transplantation lymphoproliferative disord

107 yelinating and nonmyelinating Schwann cells (NMSCs) of transgenic mice.

108 yelinating and nonmyelinating Schwann cells (NMSCs), NMSCs represent the most abundant Schwann cell (

109 E), P(VDF-TrFE)/other Na-Mn-Sn-S chalcogels (NMSC-2 and NMSC-3 with [Sn(2)S(6)](4-):Mn(2+) molar rati

110 ion, Clinical Modification (ICD-9-CM) codes, NMSC treatment Current Procedural Terminology (CPT) code

111 d 29 freshly excised biopsies from confirmed NMSC lesions in patients presenting for treatment.

112 e chose 66 isolates from four well-described NMSC outbreaks that occurred in the United States from 1

113 ly improved accuracy and precision to detect NMSC.

114 by sensitivity and specificity of detecting NMSC using DSCMs vs standard frozen histopathologic spec

115 sensitivities and specificities of detecting NMSC were 90% (95% CI, 89%-91%) and 79% (95% CI, 52%-100

116 Not all immunosuppressed patients develop NMSC, however, and in those that do, the rate of accrual

117 the BsmI SNP were twice as likely to develop NMSC than participants with no mutation (OR, 2.04 [95% C

118 One hundred six (4.3%) patients developed NMSC between 1984 and 1997.

119 tary and 9 nonhereditary survivors developed NMSC.

120 d with RT are at highest risk for developing NMSC.

121 patients are at increased risk of developing NMSCs with aggressive subclinical extensions (NMSC-ASE),

122 al Care Survey database was used to estimate NMSC-related office visits for 2012.

123 Age-standardized (Europe) NMSC incidence was 119/100,000 for women and 145/100,000

124 ng 83 posttransplant malignancies (excluding NMSC) that occurred over a median (IQR) of 6 (3-9) years

125 nt neoplasm (SMN; ie, malignancies excluding NMSC) of 20.3% (95% CI, 13.0% to 27.6%) at 15 years comp

126 I, 0.71-1.36) for all malignancies excluding NMSC.

127 I, 0.83-1.59) for all malignancies excluding NMSC.

128 2.78-6.59) and for any malignancy excluding NMSC (SIR, 4.16; 95% CI, 1.67-8.57).

129 and whose SN1 was an invasive SMN (excluding NMSC).

130 MSCs with aggressive subclinical extensions (NMSC-ASE), which may extend aggressively far beyond conv

131 ocular sequelae due to nonperiocular facial NMSC.

132 The incidence of the first NMSC was similar in the SRL and CNI groups (HR: 0.92; 95

133 rticipants entered the cohort at their first NMSC diagnosis and were observed through 2008.

134 survivors was 4.5% for melanoma and 3.7% for NMSC; for nonhereditary survivors, it was 0.7% and 1.5%,

135 nal attributable risk were 3.0% to 21.8% for NMSC and 2.6% to 9.4% for melanoma, corresponding to mor

136 .15-1.49), and 1.89 (95% CI, 1.25-2.86); for NMSC, 1.12 (95% CI, 1.07-1.16), 1.09 (95% CI, 1.05-1.13)

137 ese findings have important implications for NMSC screening and prevention.

138 cohort study of patients undergoing MMS for NMSC, larger preoperative tumor and postoperative defect

139 ignificantly elevated SIRs were observed for NMSC and NHL in those treated with immunosuppressive age

140 s been described as a noninvasive option for NMSC.

141 ber of persons with at least 1 procedure for NMSC increased by 14% (from 1,177,618 to 1,336,800) from

142 The age-adjusted US mortality rate for NMSC arising on nongenital skin from 1969 to 2000 was 0.

143 e patients that are at an increased risk for NMSC and who may therefore be good candidates for preven

144 of this study suggest an increased risk for NMSC-ASE lesions in IS patients, especially in SOTRs and

145 e polymorphisms increase a person's risk for NMSC.

146 dures in Medicare beneficiaries specific for NMSC increased by 14% from 1,918,340 in 2006 to 2,191,10

147 We conclude that, for NMSC, quality-of-life outcomes were similar after excisi

148 ivity, specificity, and accuracy of TPFM for NMSC biopsies were evaluated compared with conventional

149 of persons in the United States treated for NMSC at 3,315,554.

150 e quality-of-life outcomes of treatments for NMSC.

151 Positive predictive values for NMSC ascertainment were calculated.

152 may be effective chemopreventive agents for NMSCs.

153 of lung SCs and suggest a potential role for NMSCs in lung inflammation.

154 ese data indicate that common treatments for NMSCs were at least 95% effective, and further studies a

155 tumor-free "margin" skin were obtained from NMSC patients undergoing excision and the mtDNA from the

156 be placed on reducing mortality from genital NMSC while continuing to stress reduction of excess sun

157 We evaluated the odds ratio of having NMSC-ASE lesions in IS patients (SOTRs, HIV, hematologic

158 er mean daily UVR was associated with higher NMSC incidence rates; this was greater in men than women

159 of UVB-induced SCC and BCC, as well as human NMSC from sun-exposed sites, to investigate the expressi

160 In NMSC the prevalence of EMAST was higher in tumors that h

161 There was a decline (P<0.001) in NMSC 10-year cumulative incidence rate in RTRs over the

162 recent advances, and areas of controversy in NMSC and Merkel cell carcinoma of the head and neck.

163 on against oxidative stress are important in NMSC development in immunosuppressed patients and may be

164 TLA4 locus may be etiologically important in NMSC, the most prevalent malignancy in the United States

165 ure levels, UVB confers a modest increase in NMSC risk, much less than that observed with PUVA.

166 n development are not considered relevant in NMSC etiology, and remain poorly investigated.

167 Appropriate modeling of incidence trends in NMSC among RTRs is a valuable surveillance exercise for

168 approach was used to estimate the trends in NMSC rates that adjusted for changes in the RTR populati

169 of UVR explained most of the variability in NMSC incidence: 82% for basal cell carcinoma (BCC) and 8

170 arch into unexplained regional variations in NMSC incidence.

171 Neither incident NMSC nor melanoma rates differed between treatment (haza

172 , abatacept, or rituximab after the incident NMSC surgery.

173 occurring 1 year or more after the incident NMSC using Cox proportional hazards regression models.

174 rituximab were not associated with increased NMSC risk.

175 ogression of UVB- but not chemically induced NMSC, a role at least partially accounted by effects of

176 4-NQO reflects susceptibility to UV-induced NMSC.

177 t MIF plays an important role in UVB-induced NMSC development and progression.

178 nsory pain pathway primarily via influencing NMSC function, which in turn modulates the structure and

179 sarcoma and nonmelanotic skin malignancies (NMSC) frequently undergo remission/regression after conv

180 In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis.

181 Most NMSCs were on the head/neck, whereas melanomas were more

182 ng and nonmyelinating Schwann cells (NMSCs), NMSCs represent the most abundant Schwann cell (SC) popu

183 edly decreased in patients who developed non-NMSC, PTLD, or non-PTLD compared with patients who did n

184 after HT, overall de novo malignancies (non-NMSC) occurred in 31% of CNI patients and in 13% of SRL

185 In contrast to nongenital NMSC, mortality rates among black men were twice that of

186 lanoma skin cancer (NMSC) or a nonperiocular NMSC causing a complication requiring eyelid surgery wer

187 s; and type of NMSC, number of nonperiocular NMSCs, ophthalmologic findings, and periocular sequelae

188 PRS of nontransplant NMSC is predictive of case:control status and time to NM

189 I had three times the incidence (P<0.001) of NMSC compared with NI.

190 lative risk, 2.82; 95% CI, 1.07-7.44) and of NMSC (relative risk, 3.46; 95% CI, 1.08-11.06).

191 confidence interval [CI], 1.66-5.10) and of NMSC (standardized incidence ratio, 4.59; 95% CI, 2.51-7

192 Histologically confirmed cases of NMSC (n=900) were matched to controls (n=900) on the bas

193 Of the medical records of 3148 cases of NMSC that were reviewed, 60 showed inflammation in histo

194 Cases of NMSC were confirmed in 96.5% of ICD-9-CM-identified pati

195 o UV radiation (UVR) is the primary cause of NMSC, although the pattern of exposure that gives rise t

196 screen use, the quest for chemoprevention of NMSC in the general population has been unsuccessful.

197 e, 49-94 y]) with histologic confirmation of NMSC were treated with (188)Re-ERT, with 181 lesions tre

198 gene are associated with the development of NMSC and the demographic characteristics of the particip

199 ol in human keratinocytes and development of NMSC.

200 population to facilitate early diagnosis of NMSC and reduction in sun exposure.

201 espective cancer registries for diagnosis of NMSC, mainly squamous cell carcinoma (SCC) and basal cel

202 tions associated with the staged excision of NMSC was performed from September 8, 2008, to September

203 om genome-wide association studies (GWAS) of NMSC in a general, nontransplant setting, can predict ri

204 The risk factors of family history of NMSC (OR, 1.66 [95% CI, 0.90-3.07]) and light hair color

205 Persons with a history of NMSC are at increased risk of cancer mortality.

206 In subgroup analyses, women with history of NMSC assigned to CaD had a reduced risk of melanoma vers

207 logical mechanisms are unknown, a history of NMSC should increase the clinician's alertness for certa

208 entional risk factors, a baseline history of NMSC was associated with increased total cancer mortalit

209 However, in women with history of NMSC, CaD supplementation reduced melanoma risk, suggest

210 For patients with a history of NMSC, data are limited on the effect of these drugs on t

211 was not observed in women without history of NMSC.

212 The incidence of NMSC also increased among patients with IBD (IRR, 1.46;

213 ough nationwide estimate of the incidence of NMSC and provides evidence of continued increases in num

214 Incidence of NMSC in the US population in 2012 and BCC and SCC in the

215 The incidence of NMSC in white populations worldwide as reported in popul

216 provided age- and sex-specific incidence of NMSC in white populations worldwide was systematically r

217 cium did not reduce the overall incidence of NMSC or melanoma.

218 s, there was an increase in the incidence of NMSC with time since transplantation.

219 Location of NMSC included head and neck (43%), back (24%), chest (22

220 PTLD, and subsequent primary occurrences of NMSC after HT.

221 ed risk of subsequent primary occurrences of NMSC compared with that of CNI (adjusted HR: 0.44; 95% C

222 first and subsequent primary occurrences of NMSC post-HT.

223 esis, may be involved in the pathogenesis of NMSC.

224 port a role for bcl-2 in the pathogenesis of NMSC.

225 between BCC and SCC and allow prediction of NMSC incidence for data-poor regions and under changing

226 Statistically significant predictors of NMSC-ASE lesions such as age, location, and IS status ca

227 ful in the early treatment and prevention of NMSC with chemopreventive agents (for those with the Bsm

228 of MIF in the development and progression of NMSC, we exposed MIF(-/-) BALB/c mice to acute and chron

229 s been identified as a critical regulator of NMSC.

230 gs was significantly associated with risk of NMSC (HR, 1.49; 95% CI, 1.03-2.16).

231 ed with thiopurines had an increased risk of NMSC (OR, 1.85; 95% CI, 1.66-2.05).

232 mab was associated with an increased risk of NMSC and other cancers.

233 Adjusted for other medications, the risk of NMSC increased with 1 year or more of methotrexate use (

234 creased by use of biologics, and the risk of NMSC is increased by use of thiopurines.

235 may be associated with an increased risk of NMSC that may be specific to BCC.

236 nificantly associated with increased risk of NMSC: rs2228527 (odds ratio (OR) 1.57, 95% confidence in

237 SN1 of NMSC identifies a population at high risk for invasive S

238 nificant predictor of case:control status of NMSC posttransplant (OR = 1.61; adjusted P = .0022; AUC

239 Using a population-based study of NMSC we found that oral steroid use is associated with n

240 carcinoma (SCC) of the skin is a subtype of NMSC that shows a greater potential for invasion and met

241 During Mohs micrographic surgery of NMSC with the examination of frozen sections, histologic

242 ve agents received at diagnosis; and type of NMSC, number of nonperiocular NMSCs, ophthalmologic find

243 posure that gives rise to different types of NMSC appears to vary.

244 luence odds of developing the major types of NMSC, basal cell carcinoma (BCC) and squamous cell carci

245 -2 expression may prevent the development of NMSCs.

246 ciatic nerves; however, there was no loss of NMSCs that ensheathe these axons.

247 We estimate the total number of NMSCs in the US population in 2012 at 5,434,193 and the

248 As for the number of NMSCs, we identified two independent SNPs on chr6 and on

249 n in numbers of AKs and decreased numbers of NMSCs in the treated arm (2 NMSCs) versus the untreated

250 The impact of screening on NMSC incidence in Schleswig-Holstein, Germany, is analyz

251 The impact of screening on NMSC incidence in Schleswig-Holstein, Germany, is analyz

252 sed the effects of 0.1% topical tretinoin on NMSC.

253 e-control studies, patients with melanoma or NMSC were matched to 4 patients with IBD without melanom

254 d to 4 patients with IBD without melanoma or NMSC.

255 For overall NMSC diagnosis, TPFM had a 93% sensitivity (95% CI, 66%-

256 nsplant follow-up, and background population NMSC incidence rates.

257 ociation between HLA type and posttransplant NMSC in 2,433 renal-transplant recipients in a Northern

258 nificant predictor of time to posttransplant NMSC (adjusted P = 9.39 x 10(-7) ; HR = 1.41, concordanc

259 7 157 recipients, by 3 years posttransplant, NMSC was diagnosed in 5.7%, viral-linked cancer in 1.9%,

260 A model was created to predict NMSC diagnoses using known risk factors and, potentially

261 n = 355) without having a subsequent primary NMSC.

262 t study of consecutive patients with primary NMSCs treated with the most common treatments, in two pr

263 Individuals with a prior NMSC history are at increased risk for subsequent NMSC,

264 in the dermatology clinic for biopsy-proven NMSC of the head and neck during the study period, and 1

265 ligible CCSS participants, 213 have reported NMSC; 99 patients (46%) have had multiple occurrences.

266 tigation of the 3895 bp deletion in the same NMSC samples used in a previous study of the 4977 bp com

267 ssociated with an increased risk of a second NMSC (hazard ratio [HR], 1.60; 95% CI, 1.08-2.37).

268 nti-TNF do not increase the risk of a second NMSC in patients with IBD.

269 A second NMSC occurring 1 year or more after the incident NMSC us

270 88 with IBD), the incidence rate of a second NMSC per 1000 person-years was 58.2 (95% CI, 54.5-62.1)

271 ti-TNF use may increase the risk of a second NMSC when used with methotrexate for RA.

272 ssociated with an increased risk of a second NMSC.

273 ticle reports on the occurrence of secondary NMSC as a long-term effect of cancer therapy in survivor

274 Measured CD4 count, VL, and subsequent NMSC (BCC and SCC).

275 history are at increased risk for subsequent NMSC, but the magnitude of risk and its relation to HIV

276 s/mL) had a 44% increased risk of subsequent NMSC overall and a 222% increase risk of SCC in particul

277 rogression may be associated with subsequent NMSC risk.

278 om 1996-2008 to determine risk of subsequent NMSCs in relation to CD4 count and VL.

279 d an increased risk of malignancy other than NMSC (relative risk, 2.82; 95% CI, 1.07-7.44) and of NMS

280 xpected incidence of malignancies other than NMSC (standardized incidence ratio, 3.04; 95% confidence

281 The NMSC-1 can be used as an efficient filler in poly(vinyli

282 nt molecular subtyping standard, most of the NMSC outbreaks have been caused by isolates of several c

283 aths in the United States were attributed to NMSC from 1969 to 2000.

284 redictive of case:control status and time to NMSC posttransplant.

285 redictors of case:control status and time to NMSC posttransplant.

286 filler content of 0.5 wt %, the P(VDF-TrFE)/NMSC-1 nanocomposite exhibits superior piezoelectric per

287 e fluoride-trifluoro ethylene) [P(VDF-TrFE)]/NMSC-1 nanocomposite, enhancing crystallization of P(VDF

288 tomic analysis revealed the existence of two NMSC populations (NMSC1 and NMSC2) that may participate

289 A subset of charts was reviewed to verify NMSC diagnosis, including all records from HMO-enrollee

290 sed group, the most common malignancies were NMSC (n = 11) and non-Hodgkin's lymphoma (NHL; n = 4) an

291 er case, followed by "other" cancer, whereas NMSC impacted only outpatient costs.

292 ociations with death and graft loss, whereas NMSC was associated with 33% higher mortality beyond the

293 did not develop these malignancies, whereas NMSC had no significant effect on survival.

294 he identification of factors associated with NMSC diagnosis.

295 se claims data cases were then compared with NMSC identified using natural language processing (NLP)

296 A total of 1397 patients with NMSC (978 [70%] male; mean [SD] age, 68.5 [12.4] years)

297 ohort study of 633 consecutive patients with NMSC diagnosed in 1999 and 2000 and followed for 2 years

298 twin studies in nontransplant patients with NMSC suggest a low genetic component, several genes asso

299 spective cohort study included patients with NMSC who presented for surgery at an academic MMS practi

300 ermine the association of polymorphisms with NMSC development and demographic characteristics.